Index

Note:
Abbreviations:
CBT – cognitive-behavioural therapy
MEMS – medication electronic monitoring system
OCRDs – obsessive-compulsive and related disorders
PHQ – Patient Health Questionnaire
Figures in *italics*, tables in **bold**, boxes indicated with “b.”

abuse/neglect
body dysmorphic disorder 129
of children see child abuse
dermatological presentations 56, 56–57, 57
facititious disorder (Munchausen) by proxy 57–58, 157, 200, 204
“malingering by proxy” 58
refusal of care 58, 58b
risk recognition and index of suspicion 57–58
trichotillomania and 88
of vulnerable people 56, 56–57, 57–58
vulvodynia and 175–176
accidents, danger from 56
acne
in children/adolescents 198, 203
“picker’s” (acne excoriee) 135, 136, 136
suicide risk and 52
acne excoriee 135, 136, 136
acquired perforating dermatosis 189
acute generalized exanthematous pustulosis 31
adherence (to treatment)
assessment of 33–34, 34, 34b
MEMS 33–34, 34, 34b, 35
chronic skin diseases 34, 35
definition 33, 34b
in delusional infestation 124, 125
factors affecting 36, 36
interventions 36–38
“white coat compliance” phenomenon 36–37
adjustment disorders 142–143
defining features 142–143
dermatitis artefacta comorbidity 142–143, 148
differential diagnosis 109
maladaptive coping 212, 212, 213
treatment 148
adolescents
acne in 198, 203
developmental stage 202
psychodermatology see child/adolescent psychodermatology
suicide risk 52
agoraphobia 106, 107
treatment 112
alcohol consumption/abuse 224
acute withdrawal 229–230
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) 226, 267
Alcohol Use Disorders Identification Test (AUDIT) 226, 266
alopecia
chemotherapy-induced 85–86
scarring 86, 86
suicide risk and 52
see also hair loss
alopecia areata (AA) 82–84, 83
in children 83–84, 198
psychological impact 84, 198
psychological stress as trigger 83
amitriptyline 166
anaphylaxis, undifferentiated somatoform idiopathic 161–162
angioedema 161–162
anticonvulsants 112
antidepressant medication 21–27
classes 21–22
doses and side effects 23–24, 31
indications
anxiety disorders 22, 25, 25, 26
depression 22, 23, 110–111
nodular prurigo 192
OCRDs 25, 26, 27
somatic symptom and related disorders 27, 28, 157
SNRIs 21–22, 23, 184
SSRIs see selective serotonin reuptake inhibitors (SSRI)
tricyclic (TCAs) 21–22, 24
antipsychotic medications 27–30, 29, 30
indications
delusional disorders 27, 29, 30, 123, 124, 125
delusional infestation 124, 125
nodular prurigo 192
trichotillomania 88
practical tips 125
prescribing and monitoring 27, 30
side effects 27, 30, 31

Index

anxiety
acute 22, 25
chronic 22, 26
differential diagnosis 109
management 22, 25, 26, 111–112
in psoriasis 90
anxiety disorders 105
agoraphobia 106, 107
biological factors associated 108
cancer phobia 213
in chronic skin disease 104–113
clinical assessment 108–109
differential diagnosis 109
management 109–112
pathogenesis 108
DSM-5 classification 105, 105–107
future research 112
generalized see generalized anxiety disorder (GAD)
panic disorder 106
Patient Health Questionnaire (PHQ-2) 15b, 92–93, 108, 246–249
psoriasis and 90
psychological factors associated 108
screening questionnaires 108, 243
social anxiety disorder 107, 107, 112
social factors associated 108
specific phobia 106, 107
treatment 109–112, 110b, 111–112
antidepressants 22, 25, 26, 110–111
clinician’s role 110
failure to respond 111
psychological therapies 110
self-help and education 110
SSRIs for 25, 26
trichotillomania and 199
anxiolytics 24–25, 25
dermatologic side effects 31
aprepitant 192
assessment (psychodermatological) 11
of adherence see adherence
biopsy and laboratory evaluation 16–17, 17b
consultation room 11–12
expectations, setting 11
follow-up visits 17
initial consultation 11–17
mental status 13, 13b, 17, 17b
physical examination 16, 16
psychiatric see psychiatric disorders
psychological see psychological assessment
tools/standardized measures 8, 15–16
dermatological disease-specific 8, 44
dermatology-specific 8, 44
non-dermatology specific 8, 44
psychiatric disorders 15, 15–16, 15b, 16b
psychological 8, 42, 44, 46, 64
see also individual conditions
atopic dermatitis/eczema
adults/older children 66–67
in children (young) 69, 197–198, 203, 204
nodular prurigo and 187, 190–191
quality of life and 198
stress and 68
treatment
educational interventions 203, 204
habit reversal training see The Combined Approach
psychological therapies 203, 204
topical treatment 67–68, 190–191
autism and learning difficulties 200, 204
avoidance behaviour 154
basal cell carcinoma 210, 212, 213
basic psychological therapies 45–46
Beck’s cognitive triad 143
behavioural theory, in depression 216
behavioural therapy 66
nodular prurigo 192
see also cognitive-behavioural therapy (CBT); habit
reversal training (HRT)
benzodiazepines
acute anxiety treatment 25
side effects 22, 25
biopsy 16–17
biopsychosocial model
child/adolescent psychodermatology 200–201, 201
somatic symptom and related disorders 156
bipolar disorder 105, 105–106
dermatitis artefacta, comorbidity with 143
differential diagnosis 109
treatment 112
body dysmorphic disorder (BDD) 127–133, 159
aetiology 129
cancer phobia 213
clinical features 127, 128, 128b, 129, 130, 134
dermatological treatments sought 127, 128b, 131–132, 132b
detection and assessment 129, 130b
questionnaires 129, 130b, 256–259, 260
diagnostic criteria 127, 128b
engagement 130, 130b
epidemiology 128
hair loss and 87
suicide/suicidal ideation in 52, 127
treatment 130–132, 132b
CBT 130, 131–132, 131b
evidence-based treatment options 130
body image, suicide risk and 52
body odour see smell and body odour, disorders related
to
borderline personality disorder 14b
botulinum toxin treatment in depression 216–219
treatment and pathogenesis 216–217, 218
oxygen sign 216, 217
treatment 217, 217–218
breathing techniques (relaxation) 46
British Association of Dermatologists (BAD)
measures for psychological assessment 64
psychodermatology working party report 7–8, 45
bupropion 22, 24
burning mouth syndrome (BMS) 180–185
assessment 181, 182, 183
defining features 180, 182
pathogenesis 182
prevalence 180
secondary causes 180, 181
treatment 183
treatment 182, 184–185
therapeutic ladder 184, 185
burns scarring in children 198
“butterfly sign” 186, 187
cacosmia 159, 160, 161
CAGE questionnaire 226, 238
calcipotriol ointment 191
camouflage 99, 99–100b
in body dysmorphic disorder 127
dermatitis simulata and disfigurement, living with 99, 99–100b
hair loss 89
in skin cancer 209, 211
cancer
chemotherapy-induced alopecia 85–86
phobia 213–214
psychosocial challenges of 207, 207
see also psychodermato-oncology; skin cancer
capsaicin cream 165, 166, 191
carbamazepine 166, 168
cardiac events, antipsychotics and 27, 30
cardiovascular disease (CVD) 90, 92
Changing Faces (UK) 97–98
FACES approach see disfigurement, living with
Charles E. Holman Foundation (CEHF) 220
chemotherapy-induced alopecia (CIA) 85–86
child abuse 56–57, 57
body dysmorphic disorder and 129
vulvodynia after 175–176
child(ren)/adolescent(s)
abuse/neglect see child abuse
assessment of illness 200, 201
developmental stages 200–202
adolescence (age 12–18 years) 202
early middle-childhood (age 6–8 years) 201–202
factors affecting 200, 202, 202
infancy (age 0–1 years) 201
child/adolescent psychodermatology 197–205
adherence in chronic skin diseases 37
assessment 200, 201
biopsychosocial model 200–201, 201
autism and learning difficulties 200, 204
classification and clinical presentations 197–200
conditions
acne 198, 203
alopecia areata 83–84, 198
atopic eczema 69, 197–198, 203, 204
burns scarring 198
delusional infestation 117–118, 122
dermatitis artefacta 144, 199–200, 204
Munchausen by proxy 57–58, 157, 200, 204
nail biting/onychophagia 199
neurotic excoriations 199
OCRDs 200, 204
self-harm (skin mutilation) 200, 204
skin picking 199, 200
trichotillomania 87–88, 199, 204
vitiligo 198
developmental perspective see children/adolescents
nature/nurture factors 201
parenting and 201–202, 203, 204
psychiatric disorders underlying skin disorders 198–200, 199
treatment 204–205
refusal of care 58, 58b
skin disorders causing psychological problems 197–198, 198
inventions 203–204
skin disorders exacerbated by stress/psychosocial factors 198, 203
interventions 203
treatment 202–204, 203, 204
see also The Combined Approach
chronic eczema 66, 67
chronic idiopathic mucocutaneous pain syndromes 173–179
common characteristics 174b
differential diagnosis 174
see also peno-scrotodynia (PSD); vulvodynia
chronic pain syndrome, therapeutic ladder 184, 185
chronic pelvic pain syndrome (CPPS) 176, 177
chronic prostatitis (CP) 176, 177
chronic skin diseases
adherence to treatment 34, 35
mood/anxiety disorders see anxiety disorders; mood disorders
written action plans (WAPs) 37
citalopram 22, 23, 157
classification (psychiatric disorders) 5–6
DSM-IV/DSM-5 see DSM-IV and DSM-5
ICD-10 6, 14–15
clinician disquiet 109
clonazepam 184
cognitive-behavioural model, health anxiety 154, 155b
cognitive-behavioural therapy (CBT) 47, 47–48, 48, 75
applications
body dysmorphic disorder 130, 131–132, 131b
dermatitis artefacta 148
obsessive-compulsive disorder 138
in psychodermato-oncology 214
somatic symptom and related disorders 154, 157
trichotillomania 88
children 203
cognitive and behavioural techniques 48
phases 75
self-help courses 48
structure 75, 139
cognitive interventions 48, 139
cold injuries 171
The Combined Approach 66–70, 67b
adults/older children
assessment 67
follow-up 68–69
habit reversal 68, 68
dermatitis neglecta 56
dermatitis simulata 146
dermatological conditions
  chronic, mood/anxiety disorders and see anxiety disorders; mood disorders
  disfigurement see disfigurement, living with
  self-help see self-help (psychological)
  non-suicidal harm 53
  psychiatric disorders presenting with 3, 4, 5, 115–151
  psychiatrist’s approach 18
  psychiatric risk 50, 51–52
  psychologist’s approach to 18, 40–41
  psychosocial issues in 72
  quality of life and 73, 75, 198, 210
  with secondary psychiatric disorders 3, 4, 5, 79–113
  as signs of abuse 56, 56–57, 57
  suicide/suicidal ideation 51–52
  see also individual conditions
dermatological medications, psychiatric side effects
  30, 30
dermatological pathomimicry 146
dermatologists
  access to psychological therapies 48–49
  risk assessment (psychiatric) 58–59
  Dermatology Life Quality Index (DLQI) 93, 239–240
detention, Mental Health Act (MHA) 54b
  Diagnostic and Statistical Manual of Mental Health Disorders (DSM) see DSM-IV and DSM-5
dialectical behaviour therapy (DBT) 148
  Dimensional Obsessive-Compulsive Scale (DOCS) 137, 252–255
disfigurement, living with 97–103
cultural perspective 98
definition 97
  FACES approach see FACES approach
  healthcare professionals’ role 102, 102, 103b
  interpersonal difficulties 97–98
  intrapersonal difficulties 97
  patients’ experience 98–99, 99b
  protective factors 99
  skin camouflage 99, 99–100b
  skin cancer surgery and 208–209, 209, 210
  dissociative disorders 155b, 157b
distress 40, 104
  cancer 206, 207–208
  in children 198, 203–204
  mood/anxiety disorders and see anxiety disorders; mood disorders
  Distress Thermometer for skin cancer 207, 265
doxepin cream 166
  “drip sign”, dermatitis artefacta 144–145, 145
  drug side effects see side effects of medication
  DSM-IV and DSM-5 5–6
  adjustment disorders 142
  anxiety disorders 105, 105–107
bipolar disorder 105, 105
  body dysmorphic disorder 127, 128b
dermatitis artefacta 142, 143b
  DSM-IV-TR axes 6
dysthymia 105, 106
  factitious disorder 143b, 200
  generalized anxiety disorder 107
  major depression 105, 105
  mood disorders 104, 105–106
  olfactory reference syndrome 159
  panic attack/disorder 106
  personality disorders 14–15
  social anxiety disorder (social phobia) 107
  somatic symptom and related disorders 153
  specific phobia 106
  substance use disorder 225, 225b
  trichotillomania 88, 199
duloxetine 184, 184
dysesthetic syndromes 164–172, 165b, 221
  treatment 164, 166
  see also erythromelalgia; sensory mononeuropathies; trigeminal syndromes
dysthymia
differential diagnosis 109
  DSM-5 classification 105, 105–107
eczema
  atopic see atopic dermatitis/eczema
  information resources 70b
  elderly patients, antipsychotics 27
electronic Targeted Intervention for Psoriasis (eTIPS) 94
  EQ-5D-5L 241–242
erythromelalgia 170–171
  assessment 170–171
  defining features 170, 170
  pathogenesis 170
  treatment 171
  ethical issues 8
  examination see history and examination
  excoriation disorder see skin picking disorder (SPD)
  exposure and response prevention (ERP) 138
  eyebrow trichotillomania 87
  FACES approach 100–102
    applications 102, 102, 103b
    attitude 101
    coping 101
    exchanging 101
    finding out 100–101
    social skills 101–102
  facial feedback hypothesis 216, 217, 218
  factitious disorder 157, 158
    classification in DSM-5 143b, 200
    factitious interference 145, 146
    by proxy (Munchausen) 57–58, 157, 200, 204
    pseudoangioedema 162
    skin disorder see dermatitis artefacta
  factitious interference, wounds 145, 146
  family therapy, systemic 48
female pattern hair loss (FPHL)  81, 84–85, 85
financial issues, clinic setup  7
follow-up visits  17
adherence and  36–37
friction scarification  145
gabapentin  165, 166, 192
generalized anxiety disorder (GAD)  107, 107
habit reversal training (HRT)  47, 66–71
components  67–68, 139
nursing interventions  76, 76
skin conditions  70–71
atopic eczema see The Combined Approach
hair pulling disorder  139
nodular prurigo  192
skin picking disorder  139
haemorrhage, central interference  145, 146
hair disorders  81, 82
hirsutism  86, 86b
see also hair loss; trichotillomania
hair loss  81, 82
alopecia see alopecia
chemotherapy-related  85–86
clinical assessment  81–82, 82b, 83
female pattern  81, 84–85, 85
hair cycle  81, 82
male pattern balding (MPB)  84
non-scarring  81–82, 83
psychological impact  41, 81–89
appliances/wigs  89
assessment  81
treatment  86b
psychopathology leading to  81, 87–88
body dysmorphic disorder  87
delusional infestation  87
trichotillomania see trichotillomania
quality of life measures  81
scarring  82, 86, 86
support groups  89
telogen effluvium (TE)  84
treatment  85
hair pulling  87, 87b, 135, 136–137, 139
subsets  87, 87b
see also trichotillomania
hallucinations  118
olfactory  158, 160
hand tally counter  67, 68
hand washing, rituals  136, 137
health anxiety model  154, 155b
healthcare professionals (HCPs)
assaults (of)  55–56
clinician disquiet  109
communication  93
nursing interventions see nursing interventions
patient-physician relationship  37, 45
psychiatrists  17–18
psychodermatology nurses  45, 46
supporting patients  103
see also dermatologists; multidisciplinary team (pMDT);
therapeutic relationship
high functioning autism (HFA)  200
hirsutism  86, 86b
history and examination  11–18
follow-up visits  17
initial consultation  11–17
see also assessment (psychodermatological)
histronic personality disorder  14b
“hollow history”, dermatitis artefacta  144
Hospital Anxiety and Depression Scale (HADS)  108, 207, 243
hyperlinearity  129
hyperpigmentation  189
nodular prurigo  186
notalgia paresthetica  164, 165
hypersensitivity reaction  31, 31
hypertrophic lichen planus  189
hypochondriasis  153, 155b, 157b
hypomania  105
ICD-10  6, 14–15
“illness anxiety disorder”  153, 155b, 157b
immunosuppressant agents  191
infancy developmental stage  201
infestation, delusional see delusional infestation
isotretinoin, for acne  203
laboratory evaluation  16–17, 17b
lenalidomide  191–192
lidocaine patch  166
liquid nitrogen cryotherapy  191
Lyme disease  221
Macmillan Cancer Support  209, 211
Maggie’s Cancer Centres  210
major depression  105, 105
diagnosis (mnemonic for)  16b
maladaptive coping  212, 212, 213
male pattern balding (MPB)  84
malingering  158, 158
“malingering by proxy”  58
mania  105
Massachusetts General Hospital (MGH) Hairpulling Scale 137, 261–262
medical history  12, 144
“medically unexplained” symptoms (MUS) see somatic symptom and related disorders
medication electronic monitoring system (MEMS) 33–34, 34, 34b, 35
medicolegal issues  8
melanoma, malignant  56, 206, 207
needed care refusal  58b
skin graft  211
suicide risk  52
see also skin cancer
Mental Health Act (MHA)  54b
mental status
assessment of patient  13, 13b, 17, 17b
Mini Mental State Examination  244–245
meralgia paresthetica 165–167
assessment 167
defining features 165, 167
pathogenesis 167
treatment 167
metabolic syndrome, antipsychotics and 27, 30
milnacipran 184
mindfulness 61–62, 94, 131
Mini Mental State Examination 244–245
mirtazapine 22, 24
mood disorders, in chronic skin disease
clinical assessment 108–109
differential diagnosis 109
distress and 104
DSM-5 classification 104, 105–107
future research 112
management 109–112
failure to respond 111
pathogenesis 108
skin disease interaction 109, 143
see also bipolar disorder; depression
mood stabilizers, dermatologic side effects 31
Morgellons disease 122, 220–223
assessment and treatment 222
“bug” patients 221, 222
case definition 221b
defining features and pathogenesis 220–221, 221b
differential diagnosis 220, 221
“fiber” patients 221–222
Morgellons fibers 122, 220, 221, 221b
multidisciplinary team (pMDT) 3–5, 5b
clinic setup considerations 7
dynamic between providers 18
for nodular prurigo 189–190
psychodermatology service delivery 6–7
in psychodermato-oncology 214
psychologist, access to 48–49
Munchausen (factitious disorder) by proxy 57–58, 157, 200, 204
nail biting, in children 199
naltrexone 192
National Institute for Health and Clinical Excellence (NICE) 208b, 209–210
nature/nurture factors 201
“needed” care, refusal 58, 58b
neurotic excoriations 199
see also skin picking disorder (SPD)
nodular prurigo 186–193
associated conditions 186–188, 188
atopic eczema 187, 190–191
clinical assessment 188–189, 189b
clinical features 186, 187
differential diagnosis 189
investigations 189
management 189–192, 190
antipruritic strategies 193
atopic dermatitis 190–191
first-line treatment options 191
multidisciplinary team 189–190
newer/third-line treatment options 191–192
psychological and behavioural therapy 192
second-line treatment options 191
pathogenesis 186–188
noradrenergic and specific serotonergic antidepressants (NaSSA) 22
norepinephrine–dopamine reuptake inhibitor (NDRI) 22
notalgia paresthetica 164–165
assessment 165
defining features 164
pathogenesis 164–165
treatment 165
nursing interventions 72–78
cognitive-behavioural therapy (CBT) 75, 75
consultations 72–73
future research 77–78
habit reversal training 76, 76
objectives 73
psychosocial issues and 72, 73b
quality of life assessment 73, 74, 75
social cognitive theory (SCT) 76, 77
obsession(s) 134, 135b
obsessive-compulsive and related disorders (OCRDs) 134–141
assessment 137, 252–255
body dysmorphic disorder see body dysmorphic disorder (BDD)
in children 199
excoriation see skin picking disorder (SPD)
pathogenesis 136–137
psychopathology 134
referral procedure 139–140, 140b
treatment 25, 26, 27
trichotillomania see trichotillomania
obsessive-compulsive disorder (OCD)
assessment 137, 252–255
contamination-related 136, 137
defining features 134, 135b
dermatological effects/disorders 134, 135b
differential diagnosis 109
pathogenesis 136
prevalence 134
treatment 138–139, 138b
odours see smell and body odour, disorders related to
olfactory reference syndrome (OFS) 159, 159b, 160
omega sign, in depression 216, 217
onychophagia, in children 199
opiate overdose 229
organizations, psychodermatology 8, 9
outpatient clinics, risk minimization 54b
oxcarbazepine 165, 166
panic attacks 22, 106, 107
panic disorder 106, 107
papulonodules 189
paranoid personality disorder 14b
parenting, psychodermatology and 201–202, 203, 204
pathological skin picking see skin picking disorder (SPD)
patient(s) assault by 55–56
decision-making, role in 157
disfiguration see disfigurement, living with expectations 11, 36
medical history 12, 144
patient–physician relationship 37, 45
psychiatric interview and 12–13
psychiatrist’s approach to 17–18
psychoeducation 37
written action plans for 37
patient education adherence (to treatment) 37
chronic skin disease and depression 110
trigeminal trophic syndrome 169
vulvodynia treatment 176
see also psychoeducation
Patient Health Questionnaires 108, 246–249
PHQ-2 15b, 92–93, 246–249
PHQ-9 93, 108, 250
PHQ-15 156, 251
peno-scrotodynia (PSD) 176–178
defining features 176–177, 177
pathogenesis 177
psychological, social and sexual aspects 177–178
treatment and prognosis 178
personality disorders
assessment 13–15
clusters/types 14b, 14–15, 143–144
dermatitis artefacta and 14b, 15, 143–144, 148
treatment 148
Person Centred Dermatology Self-Care Index (PeDeSI) 73, 74, 75
phantosmia 159, 160, 161
pharmacology see psychopharmacology
phobias cancer 213–214
social 107, 107, 112
specific 106, 107
phototherapy 191
physical examination 16, 16
pimozone 124
porphyria cutanea tarda 227
pregabalin 165, 166
pregnancy, substance misuse 230
problem-focused coping 210–211
prurigo nodularis see nodular prurigo
pruritus, neuropathic 168–169
pseudoangioedema 162
psoriasis 90–96
assessment 92–93
of behaviour 93
of beliefs 92
of mood 92–93
clinical features 91, 95
depression and 104
epidemiology 90–91
future research 94–95
pathogenesis, psychology role 91
behavioural route 90, 92
biological route 91–92
psychological functioning 90–91, 93
suicide/suicidal ideation and 90
treatment (psychological-based) 93–94
action plans for change 94, 95
electronic Targeted Intervention for Psoriasis (eTIPS) 94
principles 93–94, 93b
review 94
psychiatric disorders
assessment 12–13, 13b, 108–109
screening questionnaires/tools 15, 15–16, 15b, 16b, 108
dermatological disorders leading to 3, 4, 5, 17, 79–113
dermatological medications and 30, 30, 31, 31
dermatologists’ roles 58–59
medications with dermatological side effects 31, 31
mental status, changes in 13, 13b, 17, 17b
outpatient clinics 54b
with secondary dermatological condition 3, 4, 5, 18, 115–151
substance use/misuse and 224–225
suicide/suicidal ideation 51, 52–53, 54b
psychiatric interview 12–13
psychiatric risk, skin conditions 50
psychiatrists, approach to patient, skin symptoms 17–18
psychocutaneous history 12–13, 13b
psychodermatology 3
assessment see assessment (psychodermatological)
classification see classification (psychiatric disorders)
dermatologist, role of 58–59
interfaces 3, 4
organizations 8, 9
prevalence 3
psychiatrist, role of 17–18
psychodermatology services 3
clinic setup considerations 7
minimizing risk in outpatient clinics 54b
models 6–7
multidisciplinary see multidisciplinary team (pMDT)
nursing interventions see nursing interventions
psychodermatology nurses 45, 46
psychological interventions see psychological interventions
psychopharmacology see psychopharmacology
setting for 11–12
stepped provision 45, 46
working party report (BAD) 7–8, 45
psychodermato-oncology 206–215, 208b
assessment 206–208
screening for distress 207–208
tools/scales 207, 264, 265
cancer phobia 213–214
cooping strategies 210–212
defining features 206
future research 214
multidisciplinary team (pMDT) in 214
psychological factors and surgery 208–210, 208b, 210
psychological interventions 206, 208b, 209
cognitive-behavioural techniques 214
psychosocial challenges 207
psychosocial support 212–213
support after skin cancer surgery 209–210, 211
see also skin cancer
psychoeducation 37, 45
group, for skin cancer 212–213, 213b
substance abuse 228
psychogenic excoriation see skin picking disorder (SPD)
psychological assessment 41–45, 43
brief vs. longer assessments 43
illness beliefs 92
mood 92–93
in skin disease 40–49, 43, 43b
psoriasis 90–91, 93
Socratic questioning 41, 41b, 42b
special (“difficult”) clients 45
standardized measures 8, 42, 44, 64
psychological health, assessment 73, 75
psychological interventions 8, 45–49, 75–76
action plans for change 94
basic 45–46
CBT see cognitive-behavioural therapy (CBT)
communication 93
complex 46–48
depression/anxiety in chronic skin disease 110, 111
dermatologist access to 48–49
habit reversal therapy see habit reversal training (HRT)
in nodular prurigo 192
in nursing interventions 75, 75–76
other therapies 48
principles 93–94, 93b
psychosocial support see psychoeducation
relaxation see relaxation (therapeutic)
self-help see self-help (psychological)
social cognitive theory 76, 77
social skills training 46
stepped provision 45, 46
systemic family therapy 48
see also individual conditions
psychological issues 40–49
coping strategies see coping strategies
dermatological conditions and 40
disfigurement see disfigurement, living with
failure to respond and 111
impact of skin disease 40
motivational interviewing 45
psoriasis 90–91
psychosocial issues see psychosocial issues
quality of life and 40, 73, 75
see also quality of life
self-efficacy 76, 77
stressed, psychological 48
psychologist
access to 48–49
approach to dermatology clients 40–41
psychopharmacology 8, 21–32
adherence see adherence
antidepressants see antidepressant medication
antipsychotics see antipsychotic medication
applications in psychodermatology 21
psychiatric adverse effects 109
see also specific conditions and drugs
psychosis
cacosmia and 160
risk assessment 109
psychosocial issues 40, 41, 72, 73b, 97
disfigurement and see disfigurement, living with
paediatric skin disorders 198, 203
skin cancer see psychodermato-oncology
QT interval 27
quality of life (QoL) assessment 73, 74, 75
Dermatology Life Quality Index (DLQI) 93, 239–240
dermatological conditions 73, 75, 198, 210
disfigurement and see disfigurement, living with
factors affecting 40
psychological issues and 40, 73, 75
scarring 198
stigmatization and 40
questionnaires 238–267
anxiety disorders 108, 243
belief assessment in psoriasis 92
body dysmorphic disorder 129, 130b, 256–259, 260
depression see depression
mood/anxiety disorders in chronic skin disease 108
psychiatric disorders 15, 15–16, 15b, 16b, 108
refusal of care 58, 58b
relaxation (therapeutic) 45–46
in self-help 61–62
repetitive behaviour 200
Revised Illness Perception Questionnaire (IPQ-R) 92
risk and risk assessment (psychiatric) 50–59
dermatological conditions 50, 51–52
dermatologists’ roles 58–59
psychological disorders 42, 45, 52–53
risk recognition and index of suspicion 57–58
types of risk 50
abuse/neglect see abuse/neglect
harm to others 53, 55–56
self-harm see self-harm
suicide see suicide/suicidal ideation
risk management 53, 55
containment and monitoring 53, 54b, 55b
principles 55b
rituals 137
scabies, nodular 189
scarring
friction scarification 145
hair loss due to 86, 86
quality of life and burns 198
scratching
in children 69, 198
Combined Approach to stop see The Combined Approach
habitual 66, 67
nodular prurigo 186, 187
screening questionnaires see questionnaires
scrotodynia see peno-scrotodynia (PSD)
selective serotonin reuptake inhibitors (SSRI) 21–22, 111
in anxiety 25, 26, 110–111
in body dysmorphic disorder 130
children/adolescents 204
in depression 23, 111
in obsessive-compulsive and related disorders 26
side effects 111, 111b
in somatic symptoms and related disorders 28
in trichotillomania 88
self-efficacy 76, 77
self-harm
adolescents 200
in autism and learning difficulties 204
dermatologic conditions 53
risk assessment 13, 42, 45
self-help (psychological) 45, 60–65
applications 60, 61
anxiety/depression in chronic skin disease 110
cognitive-behavioural therapy 48
delivery 60–61, 61b
materials and resources 61, 61b
relaxation techniques 61–62
stepped care see stepped care
sensory mononeuropathies 164–167
see also meralgia paresthetica; notalgia paresthetica
serotonin and norepinephrine reuptake inhibitor (SNRI) 21–22, 23, 184
side effects of medications
adherence and 36
dermatologic drugs, psychiatric effects 30, 30
psychiatric drugs, dermatologic effects 31, 31
see also individual drugs/drug groups
skin cancer
distress assessment 207, 265
pre-/peri-/postoperative psychological factors 208, 208–210
psychological reactions to see psychodermato-oncology
psychosocial challenges of 207, 207
quality of life and 210
suicide risk 52
surgery
disfigurement 208–209, 209, 210
psychological morbidity and 208–210, 208b, 210
types 207
see also melanoma, malignant;
psychodermato-oncology
Skin Cancer Index (SCI) 207, 264
skin diseases see dermatological conditions
skin grafts 211, 212
skin mutilation see self-harm
skin picking disorder (SPD) 135, 135–136
acne excorie 135, 136, 136
assessment 138, 263
pathogenesis 136–137
patient groups/disorders
autism and learning difficulties 200
body dysmorphic disorder 127
children 199, 200
psychopharmacology 139
treatment 130, 138b, 139
types 135
Skin Picking Scale (SPS) 138, 263
smell and body odour, disorders related to 159–160
cacosmia 159, 160, 161
clinical assessment 159–160
differential diagnosis 161, 161
investigations 160–161
management 161
olfactory reference syndrome 159, 159b, 160
phantosmia 159, 160, 161
trimethylaminuria (TMAU) 159–160, 161
social anxiety disorder (social phobia) 107, 107, 112
social cognitive theory (SCT) 76, 77
social factors, depression/anxiety in chronic skin disease 108
social skills training 46
Socratic questioning 41, 41b, 42b
somatic symptom and related disorders 153–163
assessment 154–156, 155b
biopsychosocial, grid 157
PHQ-2 15b, 92–93, 246–249
PHQ-15 156, 251
biopsychosocial approach 156
defining features 153, 154b
DSM-5 classification 153
Morgellons disease and 220, 222
pathogenesis 153–154, 155b
treatment 156–157, 157b
antidepressants 27, 28, 157
types/specific disorders
angioedema 161–162
conversion/dissociative disorders 155b, 157b
delusional disorders see delusional disorders
factitious disorder 157, 158
hypochondriasis 155b, 157b
malingering 158, 158
smell/odour disorders see smell and body odour
specific phobia 106, 107
stepped-care model 62–64, 63
assessment, implications for 62–64, 64b
depression 110, 111
Stevens-Johnson syndrome 31, 31
stigmatization 40, 198
stimulus control procedures 139
stress 45
atopic eczema and 68
as factor in skin disease 3, 22, 198
hair loss and 81, 82
substance misuse/substance use disorder 224–230
assessment of dermatology patient 226, 226–228, 229
formal screening questionnaires 226, 266, 267
laboratory assessments 228
PHQ-2 15b, 92–93, 246–249
physical examination 226–228, 227, 228
categories 224
cutaneous signs 227, 227, 228
defining features 225, 225b
delusional infestation 118, 118b
differential diagnosis 109
DSM-5 criteria 225, 225b
effects on dermatology patients 224
emergency situations 229–230
“legal highs” 224
pathogenesis 225–226, 225b
prevalence 224
psychiatric disease comorbidity 224–225
treatment 228–229, 229
suicide attempt 51
suicide/suicidal ideation 50–53
in adolescents 52
body image and 52
conditions associated
alopecia and 52
body dysmorphic disorder 127
cancer phobia 52, 213
dermatological disorders 51–52, 90
psoriasis 90
psychiatric disorders 51, 52–53, 54b
protective factors 51
risk assessment 42, 45, 51–53, 56, 109
initial evaluation 51
risk factors 50–51, 52b
risk management 53, 54b, 55b
undirected/collateral danger to others 56
support groups, for hair loss 89
systemic family therapy 48
systemic lupus erythematosus 41
“talking therapy” see cognitive-behavioural therapy (CBT)
telogen effluvium (TE) 84
terra firma forme 56
thalidomide 191–192
therapeutic relationship 37, 45
in delusional infestation 120
in dermatitis artefacta 146–147, 147b
see also healthcare professionals (HCPs)
“Think–Feel–Do cycle” 93
“tic douloureux” 167
transcutaneous nerve stimulation (TNS) 165
trichotillomania 87–88
aetiology and pathogenesis 136–137
childhood abuse and 88
assessment 137, 261–262
in children 87–88, 199, 204
classification (DSM-5) 87, 87b, 88, 199
clinical features 87, 87, 135
subsets of hair pulling 87, 87b
defining features 135
prevalence 88, 135
psychopharmacology 139
treatment 88, 88b, 138b, 139
tricyclic antidepressants (TCAs) 21–22, 24
trigeminal syndromes 167–170
trigeminal neuralgia 167–168
assessment, pathogenesis 168
defining features 167–168
treatment 168
trigeminal trophic syndrome 168–170
assessment 169
defining features 168, 168–169
pathogenesis 169, 169
prevalence 169–170
trimethylaminuria (TMAU) 159–160, 161
violence, direct, intentional 55
vitiligo 5, 198
vulnerable people, abuse/neglect 56, 56–57
vulvodynia 173–176
assessment 174–175, 175
defining features 173, 174
differential diagnosis 174, 174
epidemiology 173–174
pathogenesis 175
psychological, social and sexual aspects 175–176
treatment 176
“white coat compliance” phenomenon 36–37
written action plans (WAPs) 37